Nolato Q3 Sales Rise 7% as EBITA Margin Reaches 10.2%
Nolato AB reported third-quarter 2026 sales up 7% year on year, with 3% organic growth and a 10.2% EBITA margin, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Swedish company Nolato AB reported third-quarter 2026 sales that rose 7% year on year. Adjusted for currency and acquisitions, organic growth was 3%, and the EBITA margin reached 10.2%. Net debt stood at 1.0x EBITDA at the end of the quarter.
By segment, Medical Solutions grew organically by 9%, supported by drug delivery and in vitro diagnostics. Engineered Solutions fell 3% organically, weighed down by weakness in automotive and destocking by hygiene customers. The figures are as reported by TradingView, which cites the company's release.
why it matters
For investors the split between segments matters: growth in medical supports the overall picture, while automotive weakness and higher input costs could limit profitability. Leverage of 1.0x EBITDA leaves room for further acquisitions and investment.
market impact
Nolato B shares: strong medical segment supports, automotive slump and input costs weigh
- Nolato B shares mixed — revenue and medical growth offset by automotive weakness and input cost pressure
tags
instruments
sources
- Nolato AB (NOLA_B) Q3 Sales Up 7%, EBITA Margin 10.2% — TradingView, 29 October 2026 at 06:45 UTC
- Sweco AB (publ) (SWEC_A) Q3 Sales Up 7%, EBITA Margin 10.3% — TradingView, 29 October 2026 at 06:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗